Skip to main content
. Author manuscript; available in PMC: 2020 Jan 8.
Published in final edited form as: Circulation. 2019 Jan 8;139(2):226–242. doi: 10.1161/CIRCULATIONAHA.118.034165

Figure-8.

Figure-8

VEGF165b regulates S100A8/S100A9 expression in ischemic-muscle. A-B) Flowcytometric analysis S100A8/S100A9 expression in A) non-ischemic (NGA), ischemic-muscle treated with IgG or ischemic-muscle treated with VEGF165b-Ab, B) macrophages from NGA, IGA+IgG or IGA+VEGF165b-Ab. C) CD80high M1-like macrophages in NGA, IGA+IgG or IGA+VEGF165b-Ab. A-C) n=5, One way ANOVA with Dunnett’s multiple test correction was used to determine statistical significance. D-E) qPCR analysis of D) Arg-1 and E) iNos expression in macrophages (Raw264.7) transfected with S100A8 or S100A9 plasmid and treated with IgG or VEGF165b-Ab under normal or HSS conditions. n=6. Unpaired T-test was used to determine statistical significance. *P<0.05 considered significant. F) Schematic of VEGF165b induced macrophage M1 like polarization that inhibits perfusion recovery in PAD.